EVOTEC TO SUPPORT RAPPTA IN DEVELOPING SMALL MOLECULES THAT REACTIVATE PP2A, A KEY TUMOR SUPPRESSOR
THE COLLABORATION LEVERAGES EVOTEC'S ONCOLOGY EXPERTISE AND INTEGRATED DRUG DISCOVERY AND DEVELOPMENT PLATFORM

HAMBURG, GERMANY / ACCESSWIRE / November 24, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a new multi-year drug development partnership with Rappta Therapeutics, a Finland-based biopharmaceutical company, focused on an innovative oncology target.

Under the partnership, Evotec will support Rappta's programme of developing small molecule activators of the enzyme Protein Phosphatase 2A ("PP2A"), which downregulates multiple oncogenic signalling pathways responsible for driving cancer progression. Although PP2A is a key tumour suppressor and has a critical function regulating protein de-phosphorylation and tumour growth, it has to-date been very difficult to target pharmaceutically.

Through its deep understanding of PP2A biology and the use of proprietary technology, Rappta has uniquely defined the PP2A target which has allowed them to come up with a series of first-in-class compounds which glue the three subunits of PP2A together, thus driving PP2A complex reformation and restoring its tumour suppressive function. Evotec and Rappta intend to develop the programme which is currently in the late lead optimisation stage towards IND-enabling studies over the course of their partnership.

The collaboration leverages Evotec's industry-leading integrated platform for drug discovery and development including Evotec's oncology expertise coupled with state-of-the-art technologies to maximise probability of success even in fields of cutting-edge and difficult science. Evotec receives undisclosed research funding and is eligible for success-based milestone payments.

Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: "Evotec is pleased to initiate this first collaboration with Rappta Therapeutics supporting their novel and next generation platform targeting PP2A against cancer. Evotec has a long and successful track record in the oncology field, having achieved numerous milestones including multiple pre-clinical candidates and clinical-stage assets together with our partners. We have been thoroughly impressed with the progress that Rappta has made in mapping out the PP2A target and look forward to working with them to continue their success by delivering solutions for patients with unmet medical needs."

Mikko Mannerkoski, the CEO of Rappta Therapeutics, added: "We are excited to be working on building a new platform and a novel class of pharmaceuticals to treat cancer. Rappta has a unique team whose deep understanding of PP2A biochemistry, structural biology, biogenesis, medicinal chemistry, and drug development is further supported by Evotec's capabilities. This is the perfect combination of expertise to translate these discoveries to the clinic."

ABOUT PROTEIN PHOSPHATASE 2A
Reversible phosphorylation is a fundamental mechanism controlling all cell signaling and communication and this process is regulated through the opposing actions of phosphatases (which remove phosphate groups from proteins) and kinases (which add phosphate groups to proteins). Altered cellular signaling as a result of protein hyperphosphorylation, results in the sustained growth of malignant cells and is a hallmark of human cancer development and progression. Protein Phosphatase 2A (PP2A) is a serine/threonine phosphatase that functions as a tumor suppressor by negatively regulating multiple oncogenic signaling pathways responsible for driving cancer progression. PP2A is made up of three subunits, that form a complete and active enzyme when bound together. The active enzyme is comprised of a scaffolding subunit (A), serving as the structural platform for the assembly of the catalytic (C) subunit and one substrate directing regulatory (B) subunit. In cancer, the tumor-suppressive activity of PP2A is often disrupted as a result of the inability of the three subunits to bind together correctly, rendering the PP2A enzyme inactive. This inactivation of PP2A, leads to increased oncogenic signaling, driving cancer progression and growth. Therefore, the reactivation of PP2A affords a unique therapeutic strategy to restore PP2A activity and cellular homeostasis, that can be used for the treatment of cancer and a broad range of other diseases.

ABOUT RAPPTA THERAPEUTICS
Rappta Therapeutics, a private biotech with operations in Finland and the US, is developing first-in-class anti-cancer drugs activating protein phosphatase 2A (PP2A). It has developed proprietary tools and a unique understanding of PP2A which allows it to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth, with the potential to create a new class of anti-cancer drugs. Rappta has a strong scientific, management and commercial team. Its scientific team represents world-leading expertise in PP2A. Rappta Therapeutics is backed by blue-chip investors Advent Life Sciences, Novartis Venture Fund, Novo Holdings and a family office. For more information, go to www.rappta-therapeutics.com.

ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.

FORWARD-LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com

SOURCE: Evotec AG via EQS Newswire

ReleaseID: 618169

NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Madison Technologies Inc. (OTCQB:MDEX), a brand development and business accelerator company, is pleased to announce Posto Del Sole's inaugural jewelry launch: Brookland Jewelry. Located in Brooklyn and dedicated to giving back to its borough, Brookland Jewelry has created a collection of pendants and rings that reflect the Brooklyn motto, "In Unity There is Strength." The collection offers 14kt and sterling silver jewelry choices starting at $180.

Brooklyn, NY has an estimated population of 2.6 million with a very high population density of 36,732 people per square mile. With a rich history dating back over 350 years, immigrants continue to flock to this borough, making Brooklyn a great place to launch a borough themed jewelry brand.

Brookland Jewelry's holiday advertising and social media campaign will promote the "Unity Makes Strength" collection with 25% of the sales donated to the Brooklyn based Arthur Ashe Institute for Public Health.

"We keep the Brooklyn motto close to our hearts every day. We are thrilled to partner with the AAIUH in support of its vital mission and programs," says Jennifer Garfall, Chief Creative Officer at Posto Del Sole

Visit Brooklyn Jewelry's website, or follow them on Facebook, Instagram and Twitter.

About Madison Technologies Inc:
Madison Technologies is a brand development and business accelerator company. The company is focused on select consumer good segments that are deemed underserved and offer significant growth opportunities for our company.

About Posto Del Sole
Posto del Sole is a jewelry company focused on aggregating small designer brands via innovative and participatory digital channels. Led by former Tiffany & Co. executives, our team has the best design, product development, and sourcing expertise in the industry. This breadth and depth of experience is distinctly suited to helm a diverse portfolio of designer jewelry brands unified by their superb quality and craftsmanship. You can learn more at www.pdsbrands.com.

About Casa Zeta-Jones Brand
The CZJ product line will include a custom-designed handle and cartridge system, pre-care products, exclusive shaving products, and some of the best aftercare products on the market today. The Casa Zeta-Jones brand will transcend what is often considered a chore to a more pampering and lush women's shaving experience. You can learn more at www.czjlegs.com.

Forward-Looking Statements
Forward-looking statements and risks and uncertainties discussed in this press release may contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape, or manner of our future financial condition or stock price.

CONTACT:
Jeff Canouse, MDEX, CEO
jeff@madisontech.io

SOURCE: Madison Technologies, Inc.

ReleaseID: 618065

VANCOUVER, BC / ACCESSWIRE / November 24, 2020 / Noram Ventures Inc. ("Noram") (TSXV:NRM)(Frankfurt:N7R)(OTCQB:NRVTF) is pleased to announce that the Company has continued drilling in mineralization at depth on Hole #7 (CVZ-62).

Figure 1 – LF-70 drill rig on CVZ-62 site, 2020-11-17, Brad Peek, Senior Geologist and Q.P. on site, looking northwest. CVZ-62 has 50 meters of lithium claystone and is continuing to drill in the claystones. Samples have been submitted to ALS laboratories for analysis.

The Zeus property Esmeralda Formation playa lake bed sediments are horizontal and laterally continuous strata over kilometers and each drill intersection has a large radius of influence for resource estimates. This is evident in the February 20, 2019, Updated Inferred Lithium Mineral Resource Estimate, Zeus Project, Clayton Valley, Esmeralda County, Nevada, USA NI 43-101 technical report for the Zeus property, where the radius of influence is 250 meters or greater. "The prior hole CVZ-61, intersected approximately 298ft (91m) of lithium claystone. With a specific gravity of 1.74 g/cc for the claystone material, this corresponds to ~31 million tonnes that potentially can be added to the resources from this one intersection alone" commented Anita Algie, Director and CFO.

"CVZ-61 is to the east of a NE-SW possible fault, and it appears that the fault has not affected the claystone unit in a measurable way; i.e., there is no measurable displacement along the fault. This bodes well for the rest of the drilling to the east of the fault, which will cover an area approximately the same as the current resources (at >900 ppm lithium cutoff)" stated Brad Peek, consulting geologist and Qualified Person for this and all 4 of the previous drilling phases of Noram's Zeus Lithium property.

President and CEO, Dr. Tucker Barrie visited the Project this past week and reported:

"The Fall drill program is proceeding well. At present we have an LF-70 drill rig that can produce 50-60 feet of core per 12 hour shift. We are running one shift a day at present, but we will soon be going to 2 shifts with a Longyear 44 rig that is capable of 120+ feet per shift. We are on track to complete the drill program before Christmas.

On this visit I had the opportunity to meet with our neighbors in Clayton Valley who are producers of lithium and of other resources. There is potential for synergies in the production of these resources moving forward, and we will continue to have discussions in this regard. "

As well, I met with senior geologists from the Nevada Bureau of Mines and the United States Geological Survey to update them of our activities and to hear about their research related to lithium claystone deposits in Nevada. There are many ways we can work together, including providing access to our property and drill core for detailed mineralogical studies, and working toward possible lithium symposia in Nevada in the future. It would be ideal to gather industry, academia and the geological surveys to discuss Nevada's significant lithium resources and how to increase production for the growing electric vehicle market. "

The technical information contained in this news release has been reviewed and approved by Brad Peek., M.Sc., CPG, who is a Qualified Person with respect to Noram's Clayton Valley Lithium Project as defined under National Instrument 43-101.

About Noram Ventures Inc.

Noram Ventures Inc. (TSX – Venture: NRM / Frankfurt: N7R / OTCQB: NRVTF) is a Canadian based junior exploration company, with a goal of developing lithium deposits and becoming a low – cost supplier. The Company's primary business focus since formation has been the exploration of mineral projects. Noram's long term strategy is to build a multi-national lithium minerals company to produce and sell lithium into the markets of Europe, North America and Asia.

Please visit our web site for further information: www.noramventures.com

ON BEHALF OF THE BOARD OF DIRECTORS
/s/ "Anita Algie."
Director and CFO
Office: (604) 553-2279

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release includes statements regarding, among other things, the completion transactions completed in the Agreement. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, regulatory approval processes. Although Noram believes that the assumptions used in preparing the forward-looking information in this news release are reasonable, including that all necessary regulatory approvals will be obtained in a timely manner, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Noram disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by applicable securities laws.

SOURCE: Noram Ventures Inc.

ReleaseID: 618026

TORONTO, ON / ACCESSWIRE / November 24, 2020 / Murchison Minerals Ltd. ("Murchison" or the "Company") (TSX-V:MUR)(OTC PINK:MURMF)  is pleased to announce the discovery of a new zinc, silver, gold and lead mineralization at Street Lake on the Brabant Lake project in Saskatchewan. The new mineralization consists of several grab samples collected 350 metres northwest of the northernmost tip of Street Lake during the 2020 summer prospecting program. The most significant sample was collected from a zone of extremely weathered outcrop (pictured below) where the rock has degraded almost entirely to rust coloured silt and sand, assayed 0.58% zinc, 0.17% lead and 32.4 g/t silver. The weathering was primarily affecting the mineralized zone and it is assumed that the oxidation of the sample may have significantly decreased the original zinc content of the primary rock.

Photo of Sample Location of 0.58% Zn, 0.17% Pb, 32.4 g/t Ag

Street Lake is located approximately 20 km northeast of the Brabant-McKenzie VMS Deposit. The area was staked based on a 2012 geophysical electromagnetic (EM) survey which highlighted a prospective conductor. A historic grab sample on the property collected by Great Bend Resources in 1987 assayed 1.19 g/t gold within a quartz vein. The 2020 prospecting work conducted by Murchison on the claim led to the discovery of this previously unknown zinc, lead, and silver mineralization.

The mineralization is located approximately 250 metres north-west of a series of EM conductors found along an 1,800 m long corridor observed in an airborne survey flown for First Graphite Corp. in 2012. The close proximity of the zinc, lead and silver mineralization to the EM conductors is encouraging and may indicate that the geophysical target is related to volcanogenic massive sulphide (VMS) mineralization similar to the Brabant-McKenzie Deposit. Limited historic diamond drilling by Hudson Bay Exploration and Development Company in 1977 on the far eastern extent of the conductive corridor intersected intervals of pyrite and graphite and included 3.05 metres of 0.1% zinc which is elevated well above background for the region. Follow-up prospecting is required to attempt to locate additional mineralization, and additional EM geophysical surveys are required to better locate the exact location of the historic EM conductors.

The area of deeply weathered zinc mineralization that was observed is approximately 4 m2 in size within an approximately 8 m2 outcrop. Sampling adjacent to the weathered zone in a rusty feldspar rich rock with disseminated galena and possible sericite alteration returned up to 0.38% lead and 18.1 g/t silver. An outcrop of rusty pegmatite was observed about 80 metres away and contained extensive quartz veining. Grab sampling of the pegmatite returned anomalous gold assays up to 0.38 g/t gold and 11.4 g/t silver.

Location Map of Street Lake 2020 Prospecting Results

Disseminated Fine Grained Galena Discovered Adjacent to Weathered Zinc Bearing Outcrop

Example of the Rusty Pegmatite with Anomalous Gold and Silver Assays Observed in Shallow Backpack Drill Hole

QA/QC

All rock samples were submitted to SRC Geoanalytical Laboratories in Saskatoon, Saskatchewan, Canada. They were analyzed twice using a partial and a total digest and ICP-OES. All samples were also analyzed for gold utilizing fire assay. SRC Geoanalytical Laboratories is an ISO certified and accredited laboratory.

Qualifying Statement

The foregoing scientific and technical disclosures have been reviewed by Andrew Masurat, P. Geo., and John Shmyr, P. Geo., qualified persons as defined by National Instrument 43-101. Mr. Masurat and Mr. Shmyr are independent consultants to Murchison and the Brabant-McKenzie project.

About the Brabant‐McKenzie VMS Project

The Brabant-McKenzie project is located 175 kilometres northeast of La Ronge, Saskatchewan and approximately three kilometres from the community of Brabant Lake. The area is accessed year-round via provincial Highway 102 and is serviced by grid power.

Brabant‐McKenzie VMS Deposit

The project consists of one mining lease, which hosts the Brabant-McKenzie VMS deposit, and additional mineral claims totalling 627 square kilometres, which cover approximately 57 kilometres of strike length over favourable geological horizons, multiple known mineralized showings and identified geophysical conductors.

About Murchison Minerals Ltd. (TSXV: MUR)

Murchison is a Canadian‐based exploration company focused on the exploration and development of the 100%-owned Brabant‐McKenzie zinc‐copper‐silver project in north‐central Saskatchewan. The Company also has a 100% interest in the HPM nickel‐copper‐cobalt project in Quebec. Murchison has 78.7 million shares issued and outstanding.

Additional information about Murchison and its exploration projects can be found on the Company's website at www.murchisonminerals.com. For further information, please contact:

Jean‐Charles (JC) Potvin, President and CEO
jcpotvin@murchisonminerals.com

Erik H Martin, CFO
Tel: (416) 350‐3776
info@murchisonminerals.com

Cathy Hume, CHF Capital Markets, CEO
Tel: 416-868-1079 x 231
cathy@chfir.com

Forward‐Looking Information

Certain information set forth in this news release may contain forward‐looking information that involves substantial known and unknown risks and uncertainties. This forward‐looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, the impact of general economic conditions, industry conditions, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward‐looking information. The parties undertake no obligation to update forward‐looking information except as otherwise may be required by applicable securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Murchison Minerals Ltd.

ReleaseID: 618033

DUBLIN, IRELAND / ACCESSWIRE / November 24, 2020 /

Key Highlights

Robust performance in a challenging trading environment
Further improvement in EBITDA and margin despite lower sales

Nine months ended 30 September

2020

LFL

Sales

$20.6bn

-3%

EBITDA

$3.4bn

2%

EBITDA Margin

16.60%

+100bps

Continued strong cash generation; expect year-end net debt/EBITDA of c. 1.4x
Non-cash impairment of c. $0.8bn expected in Q4
Agreement reached to divest of Brazil cement business for $0.2bn
Expect full-year EBITDA to be in excess of $4.4bn; ahead of 2019 on a LFL basis

Albert Manifold, Chief Executive, said today:

"As we continue to navigate these challenging times, the health and safety of our people remains our number one priority and is a core focus in our business each and every day. Markets continue to be impacted by the global pandemic and while we have seen some lower activity levels, I am pleased to report further improvement in trading performance, with an advance in both profitability and margins. The outlook for the coming months remains uncertain and visibility is limited, however, I am confident that we are well positioned for the challenges and opportunities that lie ahead."

Announced Tuesday, 24 November 2020

Health & Safety

As new waves of COVID-19 infections emerge across many of our markets, the health and safety of our people remains our number one priority. Our approach to workplace safety is uncompromising and our primary focus is to ensure that we provide a safe working environment for our employees, contractors and customers, enabling them to carry out their activities in accordance with the various health and safety protocols currently in place across our markets.

Trading Summary

Cumulative nine-month sales to the end of September amounted to $20.6 billion, a decrease of 3% compared with the corresponding period in 2019, maintaining the level of sales decline reported at the half year stage.

Third quarter trading in our Building Products Division was ahead, benefiting from strong residential repair, maintenance & improvement (RMI) demand in North America. While activity began to recover in Europe Materials in Q3, year-to-date sales remained behind prior year. In Americas Materials, Q3 sales performance was impacted by unfavourable weather conditions and a strong prior year comparative.

Sales (like-for-like1) change versus 2019

Americas Materials

Europe
Materials

Building
Products

Group

First half (H1)

-1%

-11%

+2%

-3%

Quarter 3 (Q3)

-7%

-2%

+4%

-3%

Nine months to September (9M)

-4%

-7%

+3%

-3%

Despite the lower sales, EBITDA for the period was $3.4 billion, up 1% on prior year and up 2% on a like-for-like basis reflecting a continued strong focus on cost rationalisation and mitigating actions to minimise the financial impacts of lower sales caused by the pandemic. The Group reported $65 million of non-recurring COVID-19 related restructuring items in the first six months of the year and we expect to incur similar costs in the second half.

EBITDA (like-for-like) change versus 2019

Americas
Materials

Europe
Materials

Building
Products

Group

First half (H1)

+20%

-28%

+11%

+2%

Quarter 3 (Q3)

+3%

+2%

+5%

+3%

Nine months to September (9M)

+9%

-14%

+9%

+2%

Trading Outlook

Based on the underlying trends in our businesses and recognising continued uncertainty across our markets, we expect full-year EBITDA to be in excess of $4.4 billion for 2020. For now, there is limited visibility into 2021, however the longer-term prospects for CRH remain positive, given our significant financial strength and operational resilience together with a portfolio of high-quality assets in attractive markets.

1 Like-for-like movements exclude the impact of currency exchange, acquisitions, divestments and non-recurring items.

Americas Materials

Nine-month like-for-like sales for our Americas Materials operations were 4% behind the equivalent period in 2019. Our North region was particularly impacted by COVID-19 restrictions earlier in the year while volumes in South were also impacted by delayed state lettings and unfavourable weather conditions. This was partly offset by healthy market fundamentals and solid backlogs in our West region along with pricing progress in most product lines. However, Q3 sales in the West region were impacted by unfavourable weather and wildfires in August and September. Our Cement business in North America experienced lower volumes in the first nine months of the year, however these were offset by pricing gains.

Like-for-like EBITDA for Q3 was ahead of 2019, resulting in nine-month EBITDA 9% ahead with solid price progression, good cost control and lower energy costs.

Key Products in Brief

Aggregates: Like-for-like aggregates volumes for the nine months were 3% behind 2019; average year-to-date prices increased by 3% with increases in all regions.
Asphalt: Delays in state lettings in the South region along with pandemic restrictions resulted in nine-month volumes 9% behind on a like-for-like basis; average prices were 2% behind impacted by lower bitumen input costs, however margins increased.
Readymixed Concrete: Volumes for the nine months were 5% behind 2019 on a like-for-like basis impacted by current year project delays along with the non-recurrence of large projects; average prices were 6% ahead.
Paving and Construction Services: Nine-month like-for-like sales in our paving and construction services business were 8% behind 2019 as solid activity in West was offset by pandemic restrictions and project delays in certain states.
Cement: COVID-19 restrictions, adverse weather conditions and lower demand from key sectors offset robust residential activity in western regions; nine-month like-for-like volumes were 1% behind 2019 while prices were 4% ahead with progress achieved in all markets.

Europe Materials

Nine-month like-for-like sales were 7% behind 2019, an improvement on the half year as trading activity recovered during Q3; however this was not sufficient to offset the impact of significant COVID-19 related government interventions and shutdowns in the second quarter. The United Kingdom (UK) which was one of the most significantly impacted markets saw some improvement in Q3 although activity levels are still below pre-COVID levels. Western European markets experienced improved activity levels in key markets as restrictions eased. Eastern European markets continued to trade well in Q3.

Like-for-like EBITDA for Q3 was ahead of prior year as improved pricing and the benefit of cost saving measures and lower energy costs offset the impact of lower volumes. Nine-month like-for-like EBITDA was 14% behind.

Key Markets in Brief

Western Europe: Despite some recovery in Q3 activity levels and continued pricing progress, nine-month sales were behind the prior year due to lower volumes which were impacted by strict COVID-19 restrictions in Q2, across a number of key markets such as the UK, Ireland and France. EBITDA was behind impacted by the lower sales, partly offset by cost rationalisation and improved cement pricing.
Eastern Europe: Nine-month sales were ahead of prior year as construction sites remained open throughout the pandemic. Higher cement volumes and improved pricing along with cost saving measures resulted in EBITDA ahead of the same period in 2019.
Asia: Despite record Q3 volumes, government shutdowns in the first half of the year resulted in lower nine-month volumes than prior year. Prices were also behind, impacted by product mix which resulted in lower sales compared to 2019. Lower energy costs along with operational and procurement initiatives resulted in EBITDA ahead for the nine months.

Building Products

Nine-month like-for-like sales were 3% ahead of 2019 reflecting strong volumes in Architectural Products, improved pricing in most platforms, benefits arising from commercial excellence, ongoing profit improvement and cost rationalisation initiatives. This resulted in strong operating leverage and like-for-like EBITDA for the nine months was 9% ahead of prior year.

Key Products in Brief

Architectural Products: Nine-month like-for-like sales and EBITDA were ahead of 2019 reflecting volume improvements in all key markets and product lines as well as selling price increases. In North America the significant increase in residential RMI demand experienced in the second quarter continued into Q3 while sales also remained robust in Europe, particularly in Germany and Poland. The businesses delivered strong operating leverage on the increased sales as price increases, disciplined cost control and the benefits of profit improvement initiatives were delivered.
Building Envelope: COVID-19 restrictions and "shelter in place" orders in key markets impacted volumes at both C.R. Laurence and our architectural glass operations, although the Q3 rate of decline softened with reduced restrictions. Nine-month like-for-like sales and EBITDA were behind 2019 as a result of lower volumes, partly offset by cost management initiatives to align costs with the lower activity levels.
Infrastructure Products: Nine-month like-for-like sales were behind prior year, driven by Q3 volume declines in North America due to slower demand in key product lines, COVID-19 restrictions in Europe earlier in the year and a downturn in the telecoms market in Australia. Despite the lower volumes, good pricing and stringent cost control resulted in nine-month like-for-like EBITDA ahead of 2019.
Construction Accessories: Nine-month like-for-like sales were behind the same period in 2019, mainly impacted by COVID-19 related business disruption in both Europe and North America. Some recovery has been experienced in recent months, particularly in Europe, while challenging market conditions continued to impact our businesses in North America. Like-for-like EBITDA was behind 2019, impacted by lower volumes and partly offset by cost reduction measures.

Profit Before Tax Outlook

We expect full-year depreciation and amortisation expense to be in line with last year (2019: $1.7 billion).

Arising from the Group's impairment testing process and as a result of the combined economic impacts of COVID-19 and Brexit, we expect to recognise non-cash impairment charges of c. $0.8 billion in our full-year results for 2020. These charges primarily relate to our UK business and our associate investment in China.

The net gain on divestments and non-current asset disposals in 2020 is expected to be c. $20 million (2019: $189 million loss).

The Group's share of profits from equity accounted entities (pre-impairment) is expected to be lower than prior year (2019: $67 million) mainly due to the divestment of the Indian joint venture along with the impact of COVID-19 restrictions on a number of operations.

Net finance costs are expected to be broadly in line with last year (2019: $490 million).

Taking each of these elements into account together with our EBITDA outlook, we expect full-year profit before tax (pre-impairment) to be ahead of 2019 (2019: $2.2 billion).

Balance Sheet Expectations

In line with our previous guidance, year-end net debt is expected to show a significant improvement on prior year (2019: $7.5 billion), to c. $6 billion resulting in net debt to EBITDA of approximately 1.4x based on robust EBITDA performance, continued strong working capital management, lower acquisition spend, lower capital expenditure in response to lower activity levels and a pause in the Group's share buyback programme.

Acquisitions and Divestments

The Group has spent c. $181 million on 14 acquisitions to date in 2020 (including deferred and contingent consideration in respect of prior year acquisitions).

On the divestment front, the Group completed seven transactions and realised total business and asset disposal proceeds of c. $263 million, inclusive of $122 million relating to the receipt of deferred proceeds from prior year divestments.

The agreement to divest our Brazil cement business for consideration of $0.2 billion is currently subject to competition authority review and the transaction is expected to close in 2021.

CRH will report its preliminary results for the full-year 2020 on Thursday, 4th March 2021.

CRH plc will host an analysts' conference call at 08:30 GMT on Tuesday, 24 November 2020 to discuss the Trading Update. To join this call please dial: +353 (0) 1 506 0650, confirmation code 1578116 (further international numbers are available here). A recording of the conference call will be available on the Results & Presentations page of the CRH website.

Contact CRH at +353 1 404 1000

Albert Manifold Chief ExecutiveSenan Murphy Finance Director

Frank Heisterkamp Director of Capital Markets & ESG

Tom Holmes Head of Investor Relations

About CRH

CRH (LSE:CRH)(ISE:CRG)(NYSE:CRH) is the leading building materials business in the world, employing c.79,000 people at c.3,100 operating locations in 30 countries. It is the largest building materials business in North America, a leading heavyside materials business in Europe and has positions in both Asia and South America. CRH manufactures and supplies a range of integrated building materials, products and innovative solutions which can be found throughout the built environment, from major public infrastructure projects to commercial buildings and residential structures. A Fortune 500 company, CRH is a constituent member of the FTSE 100 Index, the EURO STOXX 50 Index, the ISEQ 20 and the Dow Jones Sustainability Index (DJSI) Europe. CRH's American Depositary Shares are listed on the NYSE.

For more information visit www.crh.com

Disclaimer

In order to utilise the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, CRH public limited company (the "Company"), and its subsidiaries (collectively, "CRH" or the "Group") is providing the following cautionary statement.

This document contains statements that are or may be deemed to be forward-looking statements with respect to the financial condition, results of operations, business, viability and future performance of CRH and certain of the plans and objectives of CRH. These forward-looking statements may generally, but not always, be identified by the use of words such as "will", "anticipates", "should", "could", "would", "targets", "aims", "may", "continues", "expects", "is expected to", "estimates", "believes", "intends" or similar expressions. These forward-looking statements include all matters that are not historical facts or matters of fact at the date of this document.

By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future and reflect the Company's current expectations and assumptions as to such future events and circumstances that may not prove accurate.

A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, certain of which are beyond our control, as detailed in the section entitled "Risk Factors" in our 2019 Annual Report on Form 20-F as filed with the US Securities and Exchange Commission.

You are cautioned not to place undue reliance on any forward-looking statements. These forward-looking statements are made as of the date of this document. The Company expressly disclaims any obligation or undertaking to publicly update or revise these forward-looking statements other than as required by applicable law.

The forward-looking statements in this document do not constitute reports or statements published in compliance with any of Regulations 6 to 8 of the Transparency (Directive 2004/109/EC) Regulations 2007.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: CRH PLC

ReleaseID: 618085

VANCOUVER, BC / ACCESSWIRE / November 24, 2020 / FIORE GOLD LTD. (TSXV:F)(OTCQB:FIOGF)(FRA:2FO) ("Fiore" or the "Company") is pleased to report results from the current drilling program at its Gold Rock project in Nevada (Figure 1). These latest results continue to demonstrate thick intervals of oxide gold mineralization both within and outside of the current resource pit shells. We view this as encouraging in our efforts to upgrade Inferred resources and expand the overall resource envelope as part of the ongoing Feasibility Study ("FS") at Gold Rock.

Highlights from the sixty-two holes reported here include:

48.8 m of 2.17 g/t gold in hole GR20-009
16.8 m of 1.12 g/t gold in hole GR20-021
41.2 m of 0.97 g/t gold in hole GR20-027
19.8 m of 1.10 g/t gold in hole GR20-029
33.5 m of 0.89 g/t gold in hole GR20-036
19.8 m of 1.38 g/t gold in hole GR20-038
32.0 m of 1.41 g/t gold in hole GR20-049
18.3 m of 1.16 g/t gold in hole GR20-051
18.3 m of 1.19 g/t gold in hole GR20-065
38.1 m of 1.11 g/t gold in hole GR20-068

In the southern part of the deposit, cross-section 1 (Figure 2) shows one of the best Gold Rock intercepts to date in hole GR20-009, which intercepted 48.8 metres of 2.17 g/t gold just below the base of the current southern pit shell from the 2020 Preliminary Economic Assessment ("PEA"). Two other very strong intercepts, 32.0 metres of 1.41 g/t gold in hole GR20-049 and 38.1 metres of 1.11 g/t gold in hole GR20-068 were also located in the southern part of the deposit.

Cross-section 2 (Figure 3) is in the gap between the current PEA pit shells and shows stronger mineralization in the eastern limb of the Easy Junior anticline. Hole GR20-010 intercepted 10.7 metres of 0.73 g/t gold and demonstrates that mineralization remains open to the east. The goal of drilling in this area was to see if sufficient mineralization could be defined to pull the two PEA pit shells together into a single pit, and these results are encouraging in that regard, particularly if mineralization continues to be encountered along the eastern side of the anticline.

Cross-section 3 (Figure 4) runs through the former EZ Junior heap leach pad area where several holes have delineated mineralization below (GR20-029 and GR20-036) and to the east (GR20-028 and GR20-025) of the current PEA pit shell. Interestingly, the holes drilled through the former leach pad also show significant residual gold remaining in the leach pad material (e.g. holes GR20-029 with 15.2 metres of 0.32 g/t gold).

Cross-section 4 (Figure 5) again shows multiple intercepts below the current PEA pit shells in both the west and east limbs of the EZ anticline structure. Hole GR20-027 intercepted 41.2 metres of 0.97 g/t gold and 25.9 metres of 0.31 g/t, while GR20-038 encountered 6.1 metres of 0.45 g/t gold immediately followed by 19.8 metres of 1.38 g/t gold.

Tim Warman, Fiore's CEO stated, "These holes represent the first of the RC holes from the 2020 drilling program at Gold Rock, with the results continuing to show strong, consistent mineralization and excellent opportunities to expand the current resource envelope going into the Feasibility Study. Work on the FS is progressing well with the large diameter metallurgical core holes completed and in the process of being logged before being delivered to the metallurgical lab for further testing. The first round of HQ core holes has also been completed, including detailed geotechnical logging, with geological logging and sampling underway. Several exploration holes have also been drilled at the Jasperoid Creek target approximately 1.05 miles (1.7 km) north of the former Easy Junior pit (Figure 1).

We have been seeing longer than normal wait times for assays as the labs deal with COVID-19 protocols, so we plan to take a short break from drilling at Gold Rock to allow the assay lab to catch up, with several of the drills moving over to the Pan Mine in the interim. Drilling completed to date as part of the current program at Gold Rock includes approximately 105 RC holes, 20 HQ core holes, and 15 PQ metallurgical core holes. With all this activity it's going to be a busy and exciting year ahead for Fiore and we're looking forward to progressing the Gold Rock FS and providing the first detailed view of our next mine."

Complete results for the sixty-two holes referenced in this press release are shown in the table below. Note that holes GR20-017, -032, -041, -043 and -057 were drilled as pre-collars for HQ and metallurgical PQ core holes, and the assay results for the HQ and PQ core portions of these holes are still pending.

Hole

From

(m)

To

(m)

Length

(m)

Grade

(g/t Au)

GR20-001

117.35

123.44

6.10

0.96

includes

118.87

121.92

3.05

1.23

GR20-002

no significant results

GR20-003

100.58

106.68

6.10

1.02

includes

100.58

103.63

3.05

1.62

and

124.97

140.21

15.24

0.54

GR20-004

179.83

185.93

6.10

0.36

GR20-005

109.73

115.82

6.10

0.28

and

120.40

140.21

19.81

0.69

includes

129.54

132.59

3.05

2.37

GR20-006

no significant results

GR20-007

140.21

144.78

4.57

1.26

includes

141.73

144.78

3.05

1.40

GR20-008

135.64

141.73

6.10

0.25

GR20-009

155.45

160.02

4.57

0.27

and

166.12

214.88

48.77

2.17

GR20-010

108.20

111.25

3.05

0.35

and

118.87

129.54

10.67

0.73

includes

121.92

124.97

3.05

1.20

and

220.98

228.60

7.62

1.04

includes

224.03

227.08

3.05

1.94

GR20-011

no significant results

GR20-012

108.20

126.49

18.29

0.47

and

169.16

172.21

3.05

0.88

GR20-013

no significant results

GR20-014

92.96

103.63

10.67

0.39

GR20-015

no significant results

GR20-016

45.72

51.82

6.10

0.25

GR20-017

RC pre-collar for core hole

GR20-018

172.21

184.40

12.19

0.39

and

193.55

196.60

3.05

0.24

GR20-019

237.74

257.56

19.81

0.47

GR20-020

131.06

135.64

4.57

0.28

GR20-021

126.49

129.54

3.05

0.56

and

134.11

150.88

16.76

1.23

includes

140.21

144.78

4.57

2.59

and

156.97

170.69

13.72

0.73

GR20-022

no significant results

GR20-023

no significant results

GR20-024

no significant results

GR20-025

1.52

10.67

9.14

0.21

and

112.78

121.92

9.14

0.43

and

128.02

143.26

15.24

0.57

GR20-026

no significant results

GR20-027

21.34

30.48

9.14

0.43

and

149.35

190.50

41.15

0.97

includes

153.92

185.93

32.00

1.14

and

195.07

220.98

25.91

0.31

GR20-028

0.00

12.19

12.19

0.27

and

97.54

117.35

19.81

0.58

and

123.44

132.59

9.14

1.37

includes

124.97

132.59

7.62

1.50

GR20-029

0.00

15.24

15.24

0.32

and

19.81

22.86

3.05

0.60

and

164.59

184.40

19.81

1.10

includes

169.16

179.83

10.67

1.64

GR20-030

158.50

166.12

7.62

0.83

GR20-031

38.10

41.15

3.05

0.25

and

131.06

134.11

3.05

0.36

and

140.21

169.16

28.96

0.61

and

173.74

176.78

3.05

0.38

and

182.88

185.93

3.05

0.25

GR20-032

RC pre-collar for core hole

GR20-033

109.73

131.06

21.34

0.89

includes

118.87

126.49

7.62

1.51

GR20-034

no significant results

GR20-035

no significant results

GR20-036

97.54

131.06

33.53

0.89

includes

97.54

112.78

15.24

1.57

and

170.69

182.88

12.19

0.42

and

187.45

190.50

3.05

0.57

GR20-037

no significant results

GR20-038

166.12

172.21

6.10

0.45

GR20-038

176.78

196.60

19.81

1.38

includes

187.45

193.55

6.10

3.25

GR20-039

no significant results

GR20-040

135.64

141.73

6.10

1.01

includes

135.64

138.68

3.05

1.52

GR20-041

RC pre-collar for core hole

GR20-042

108.20

111.25

3.05

0.38

GR20-042

158.50

164.59

6.10

0.49

GR20-043

RC pre-collar for core hole

GR20-044

no significant results

GR20-045

no significant results

GR20-046

0.00

4.57

4.57

0.21

GR20-047

no significant results

GR20-048

115.82

120.40

4.57

0.34

GR20-048

128.02

144.78

16.76

0.51

GR20-049

108.20

140.21

32.00

1.41

includes

109.73

123.44

13.72

2.46

GR20-050

181.36

188.98

7.62

0.34

GR20-051

132.59

150.88

18.29

1.16

includes

134.11

150.88

16.76

1.23

GR20-052

no significant results

GR20-053

no significant results

GR20-054

no significant results

GR20-055

129.54

132.59

3.05

0.35

GR20-055

137.16

150.88

13.72

1.27

includes

141.73

146.30

4.57

2.68

GR20-055

275.84

286.51

10.67

0.29

GR20-056

no significant results

GR20-057

RC pre-collar for core hole

GR20-058

no significant results

GR20-059

121.92

128.02

6.10

0.53

GR20-060

80.77

94.49

13.72

0.32

GR20-060

106.68

117.35

10.67

0.68

GR20-061

0.00

19.81

19.81

0.26

GR20-061

160.02

182.88

22.86

0.72

includes

169.16

173.74

4.57

2.33

GR20-062

181.36

187.45

6.10

0.30

GR20-063

no significant results

GR20-064

143.26

149.35

6.10

0.32

GR20-065

108.20

126.49

18.29

1.19

includes

111.25

123.44

12.19

1.51

GR20-066

assays pending

GR20-067

assays pending

GR20-068

47.24

56.39

9.14

0.70

GR20-068

60.96

99.06

38.10

1.11

includes

83.82

97.54

13.72

2.33

GR20-069

assays pending

GR20-070

1.52

12.19

10.67

0.38

Assay highlights are calculated with a cutoff of 0.006 opt (0.20 g/t) Au. Highlighted intervals contain less than 10 feet (3 m) of material below cutoff grade.

The holes in this release are all reverse circulation ("RC") holes and represent an initial 45,000 feet (13,700 m) of a drilling program consisting of a mix of HQ and PQ diamond core holes as well as RC and sonic holes. Total planned footage for the drilling program to support the FS will be approximately 198,000 ft (60,000 m), with approximately 115,000 ft (35,000 m) focused on resource expansion to add Measured and Indicated resources for inclusion in the FS.

Gold Rock Project and PEA Highlights

The federally permitted Gold Rock gold project ("Gold Rock", or the "Project") is located approximately 8 miles southeast of the Pan Mine in White Pine County, Nevada. The recently released Gold Rock Preliminary Economic Assessment ("PEA") provides an updated mineral resource estimate and a base case assessment of developing the Project as a satellite open pit operation that will share significant infrastructure and management with the adjacent Pan Mine. The PEA also identifies a considerable number of opportunities to enhance the project economics as Gold Rock advances to the Feasibility stage by drilling to increase the mineral resource, further metallurgical testing aimed at optimizing recoveries, and geotechnical drilling aimed at reducing the stripping ratio. Further updates will be provided as we progress work in these areas. The PEA was prepared in accordance with Canadian Securities Administrators' National Instrument 43-101 Standards of Disclosure for Mineral Projects ("NI 43-101"). A Technical Report with the details of the PEA is available on SEDAR under the Company's profile.

Gold Rock Mineral Resource Estimate

The Company's updated Mineral Resource Estimate ("MRE"; effective date of March 31, 2020) was completed by APEX and forms the basis for the PEA. A summary of the MRE is highlighted in the table below.

Pit-Constrained Mineral Resource Summary

Resource Classification

Cut-off opt/gpt

Tons/Tonnes

Gold opt/gpt

Gold Ounces

Total Indicated

0.003/0.09

20.9/19.0

0.019/0.66

403,000

Total Inferred

0.003/0.09

3.0 /2.7

0.025/0.87

84,300

Key Assumptions, Parameters, and Methods related to the Mineral Resource Estimates:

Mineral Resources were prepared in accordance with NI 43-101 and the CIM Definition Standards (2014). Mineral Resources that are not mineral reserves do not have demonstrated economic viability.
Troy ounces per short ton ("opt") / grams per tonne ("gpt")
This estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, sociopolitical, marketing, or other relevant issues.
Open pit Mineral Resources are reported at a cut-off grade of 0.003 opt/0.09 gpt gold that is based on a gold price of US$1,500/oz. A revenue price of US$1,400 is used for the base case economic model.
The Mineral Resources are constrained by a pit shell with appropriate mining costs, processing costs, metal recoveries, and pit slope angles.
Rounding may result in apparent summation differences between tonnes, grade, and contained metal content.
Contained gold ounces are in troy ounces.

Technical Report & Qualified Persons

The scientific and technical information relating to Fiore Gold's properties contained in this news release was approved by Paul Noland (AIPG CPG-11293), Fiore Gold's VP Exploration and a "Qualified Person" under National Instrument 43-101. References to the Gold Rock project PEA are taken from the "Technical Report on the Preliminary Economic Assessment of the Gold Rock Project, White Pine County, Nevada, USA" (the "Technical Report"). The Technical Report, which is dated April 30, 2020 with an effective date of March 31, 2020, was prepared in compliance with National Instrument 43-101 – Standards for Disclosure for Mineral Projects ("NI 43-101") and is available under Fiore's profile on SEDAR at www.sedar.com and on the Company's website at fioregold.com. The report is authored by Michael B. Dufresne, , M.Sc., P.Geol., P.Geo., Gregory B, Sparks, B.Sc., P.Eng., Sam J. Shoemaker, Jr., B.S., SME Registered Member, Warren E. Black, M.Sc., P.Geo., and Steven J. Nicholls, BA.Sc., MAIG.

Corporate Strategy

Our corporate strategy is to grow Fiore into a 150,000 ounce per year gold producer. To achieve this, we intend to:

grow gold production at the Pan Mine while also growing the reserve and resource base;
advance exploration and development of the nearby Gold Rock project; and
acquire additional production or near-production assets to complement our existing operations

On behalf of FIORE GOLD LTD.

"Tim Warman"

Chief Executive Officer

Contact Us:

info@fioregold.com

1 (416) 639-1426 Ext. 1
www.fioregold.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Statements

This news release contains "forward-looking statements" and "forward looking information" (as defined under applicable securities laws), based on management's best estimates, assumptions and current expectations. Such statements include but are not limited to, statements with respect to any future mining operations at Gold Rock, including those described in the PEA, the resource expansion and drilling program, potential to upgrade inferred resources and expanding the overall resource envelope at the Gold Rock project, plans for and progress toward a Gold Rock Feasibility Study, anticipated results of drilling and studies, mineral resource estimates expectations that the Company will add additional mineral resources, improving and optimizing mineral recoveries at Gold Rock, future gold production, company outlook, goal to become a 150,000 ounce producer, goal to acquire additional production or near production assets, and other statements, estimates or expectations. Often, but not always, these forward-looking statements can be identified by the use of forward-looking terminology such as "expects", "expected", "budgeted", "targets", "forecasts", "intends", "anticipates", "scheduled", "estimates", "aims", "will", "believes", "projects" and similar expressions (including negative variations) which by their nature refer to future events. By their very nature, forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Fiore Gold's control. These statements should not be read as guarantees of future performance or results. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, as well as a number of assumptions made by, and information currently available to, the Company concerning, among other things, anticipated geological formations, potential mineralization, future plans for exploration and/or development, potential future production, ability to obtain permits for future operations, drilling exposure, and exploration budgets and timing of expenditures, all of which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement of Fiore Gold to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to vary materially from results anticipated by such forward looking statements include, but not limited to, risks related to the Pan Mine performance, risks related to the COVID-19 pandemic, including government restrictions impacting the Company's operations, risks the pandemic poses to its work-force, impacts the virus may have on ability to obtain services and materials from its suppliers and contractors; risks related to the company's limited operating history; risks related to international operations; risks related to general economic conditions, actual results of current or future exploration activities, unanticipated reclamation expenses; changes in project parameters as plans continue to be refined; fluctuations in prices of metals including gold; fluctuations in foreign currency exchange rates; increases in market prices of mining consumables; possible variations in ore reserves, grade or recovery rates; uncertainties involved in the interpretation of drilling results, test results and the estimation of gold resources and reserves; failure of plant, equipment or processes to operate as anticipated; the possibility that capital and operating costs may be higher than currently estimated; the possibility of cost overruns or unanticipated expenses in the work programs; availability of financing; accidents, labour disputes, title disputes, claims and limitations on insurance coverage and other risks of the mining industry; delays in the completion of exploration, development or construction activities; the possibility that required permits may not be obtained on a timely manner or at all; changes in national and local government regulation of mining operations, tax rules and regulations, and political and economic developments in countries in which Fiore Gold operates, and other factors identified in Fiore Gold's filings with Canadian securities authorities under its profile at www.sedar.com respecting the risks affecting Fiore and its business. Although Fiore has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements and forward-looking information are made as of the date hereof and are qualified in their entirety by this cautionary statement. Fiore disclaims any obligation to revise or update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments, except as require by law. Accordingly, readers should not place undue reliance on forward-looking statements and information.

SOURCE: Fiore Gold Ltd.

ReleaseID: 618074

ABINGDON, OXFORDSHIRE / ACCESSWIRE / November 24, 2020 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to note that the latest research on MTX110 was presented by its collaborators at the recent annual meeting of the Society of Neuro-Oncology (SNO2020 Virtual Conference). Links to the Abstracts and Posters are provided below:

PNOC015: An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-Enhanced Delivery (CED) in Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated with External Beam Radiation Therapy (ABSTRACT DDRE-21) – Lead Author: Dr Sabine Mueller, Pacific Pediatric Neuro-Oncology Consortium

The Abstract may be found at: https://academic.oup.com/neuro-oncology/article-abstract/22/Supplement_2/ii66/5960703?redirectedFrom=fulltext

The Poster may be found at: http://midatechpharma.com/uploads/pdf/pnoc015.pdf

Efficacy of Soluble Panobinostat (MTX110) in Preclinical Models of Adult Glioblastoma (ABSTRACT TMOD-27) – Lead Author: Dr David Ashley, Preston Tisch Brain Tumor Centre, Duke University, Durham NC 27710

The Abstract may be found at: https://academic.oup.com/neuro-oncology/article-abstract/22/Supplement_2/ii233/5961404?redirectedFrom=fulltext

The Poster may be found at: http://midatechpharma.com/uploads/pdf/Conlon-TMOD27.pdf

Commenting, Steve Damment, EVP R&D of Midatech, said: "These presentations provide further information on the encouraging Phase I DIPG trial results recently announced by Midatech on 19 October 2020, and preclinical efficacy data supporting the potential utility of MTX110 for the significantly larger adult glioblastoma indication."

About MTX110
MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak®) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. Based on favourable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma (SNO 2020 Abstract TMOD-27). MTX110 is delivered directly into and around the patient's tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimising systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient-derived DIPG cell lines (Grasso et al, 2015. Nature Medicine 21(6), 555-559).

For more information, please contact:

Midatech Pharma PLC

Stephen Stamp, CEO, CFO

Steve Damment, EVP R&D

Tel: +44 (0)29 20480 180

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0)20 7886 2500

Turner Pope Investments (TPI) Limited (Joint Broker)

Andrew Thacker (Corporate Broking)

Tel: +44 (0)20 3657 0050

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: midatech@investor-focus.co.uk

Edison Group (US Investor Relations)

Megan Paul

Tel: +1 (646) 653 7034

Email: mpaul@edisongroup.com

About Midatech Pharma PLC
Midatech Pharma PLC (dual-listed on LSE AIM:MTPH; and NASDAQ:MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

· Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

· MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

· MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease.

The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com

Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Midatech Pharma PLC

ReleaseID: 618087

Market players are focusing on research & development activities and employing advanced technologies to formulate nutritional formulas for infants that are rich in protein.

ROCKVILLE, MD / ACCESSWIRE / November 24, 2020 / The global plant protein ingredient market is anticipated to reflect an impressive growth rate over the forecast period of 2019-2027. The surging problem of lactose intolerance in infants in the past few years has attained traction in the plant protein ingredients market.

"Rising shift from meat-based protein sources to a plant-based protein have propelled the demand for plant-based protein ingredients market." says the Fact.MR report.

Plant Protein Ingredient Market- Key Takeaways

East Asia to reflect impressive growth pace throughout the forecast period.
Pea protein has attained noteworthy momentum in the market as a result of its high fiber attributes
The sports category is anticipated to record sales by over US$ 1.0 Billion towards the end of the assessment period.
Wheat plant protein ingredient type remains preferred among end-users.

Request a report sample to gain comprehensive market insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4507

Plant Protein Ingredient Market – Driving Factors

Growing demand from sports nutrition and weight management segments likely to propel growth.
Standardization and protein fortification will support market in long run
Growing interest in veganism continues to create substantial opportunities.

Plant Protein Ingredient Market – Constraints

Instabilities in crop production, and subsequent deficits of supplies is creating bottle neck for market growth.
Higher costs for sourcing sufficient raw material for plant protein ingredients is a significant challenge for producers.

Anticipated Market Impact by COVID-19 Outbreak

The COVID-19 pandemic is offering an unexpected surge to the plant-based protein market, all over the world. As studies reflect that COVID-19 has a devastating impact on individuals with underlying health disorders such as heart disease, hypertension, and diabetes. The plant protein-based diet could assist in reducing the virus effects on people at-risk due to the presence of an abundance amount of antioxidants, micronutrients, and macronutrients.

Explore the global plant protein ingredients market with 96 figures, 126 data tables, along with the table of contents of the report. You can also find detailed segmentation on https://www.factmr.com/report/4507/plant-protein-ingredient-market

Competition Landscape

Key market players identified in the global plant protein ingredient market include Roquette Freres S.A, Arla Foods, CHS Inc., Archer Daniels Midland Company, Axiom Foods, Inc., Glanbia plc, Sterling Biotech Ltd., Solae LLC, Cargill, Inc., A & B Ingredients Inc., and Prinova Group LLC.

A majority of players are focusing on launching innovative products and boosting their presence on social media to gain the benefits of influencer marketing. Considering the nature of the product, influencer marketing continues to be one of the key strategies for reaching the target audience.

More on the Report

The Fact.MR's market research report provides in-depth insights into the Plant Protein Ingredient market. The market is scrutinized based on product type i.e. soy protein, wheat protein, pea protein, rice protein, potato protein others; form (isolates, concentrate, other form), application (sports nutrition, clinical nutrition, infant nutrition, bakery & confectionary, fortified food & beverages and others), across five major regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA)).

Explore Wide-ranging Coverage of Fact.MR's Food & Beverage Landscape

Wheat Protein Concentrates Market: Find insights on the wheat protein concentrates market with analysis of segments, statistics, influencers, market players, and business strategies adopted over a 10-year forecast period.

Rice Protein Market: Fact.MR's report on the rice protein market offers insights on the market during 2020-2030, including restraints, revenue sources, market leaders, and market strategies.

Yellow Pea Protein Market: Read an analysis of the yellow pea protein market with insights on growth factors, opportunities, restraints, regional market forecast, regulatory policies, and strengths of market leaders.

About Fact.MR

Fact.MR is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Fact.MR is headquartered in Dublin, and has offices in Dubai. Fact.MR's latest market research reports industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1284/global-plant-protein-ingredient-market

SOURCE: Fact.MR

ReleaseID: 618187

Unaudited Results for the six months ended 30 September 2020

Corporate and Operational Update

TORONTO, ON / ACCESSWIRE / November 24, 2020 / Eco (Atlantic) Oil & Gas Ltd. (AIM:ECO)(TSX‐V:EOG), the oil and gas exploration company with licence interests in Guyana and Namibia, is pleased to announce its results for the three and six months ended 30 September 2020, alongside a corporate and operational update.

Results Highlights:

Financials

As at 30 September 2020, the Company had cash and cash equivalents of US$17.2 million with zero debt.
Eco remains fully funded for its share (15% WI net) of its planned two exploration wells at Orinduik Block offshore Guyana.
As at 30 September 2020, Eco had total assets of US$18.4 million, total liabilities of US$470,661 and total equity of US$18 million.
70% reduction in general and administrative expenses as compared to same six month period in 2019, including travel costs reduction of 82% and office cost reductions of 90% in line with previously reported COVID-19 cost discipline measures.

Operations

Multiple light sweet oil drilling prospects on the Orinduik block are currently being reviewed by the Company's and its licence partners (the "JV Partners"), with high-graded candidates being considered for the next drilling programme. The intention is to provide further definition to the Cretaceous interpretation and target selection for drilling.
On 30 June 2020, the Company and its JV Partners approved a budget in the amount of approximately US$5 million through to 31 December 2020 for 3D reprocessing based on new regional results and high grading of target selection. The Company's share of this budget is US$750,000.
The Company, together with its strategic alliance partners Africa Oil Corp., is currently reviewing and evaluating additional assets opportunities in both Africa and South America.

Outlook:

Guyana

Guyana continues to be one of the most prolific exploration regions in the world, with over nine billion barrels of oil discovered in the last five years. Eco and its JV Partners have already delivered two substantial oil discoveries on the Orinduik Block and the licence continues to offer significant upside potential.
As previously reported, Eco is fully funded for further drilling on the block and, with its JV Partners, is assessing all opportunities available to drill at least two exploration wells into the light oil cretaceous targets as soon as practical. The Company is fully aligned with its JV partners on careful target selection based on the reprocessed 3D for the next drilling campaign and Eco expects to be able to update the market on its next drilling plans in due course.

The Orinduik JV partners are Eco Atlantic (15% working interest ("WI")), Tullow Guyana B.V. ("Tullow") (Operator, 60% WI) and Total E&P Guyana B.V. ("Total") (25% WI) in partnership with Qatar Petroleum (government approval is expected imminently).

Namibia

Eco continues to benefit from a strategically significant acreage position in-country and is progressing its various work programmes on its four blocks offshore Namibia. The Company has witnessed considerable interest from multiple IOCs in Namibia.
The Company continues to monitor upcoming drilling activity in the region, which should potentially see up to five exploration wells drilled on behalf of ExxonMobil, Total, Maurel & Prom, Shell and ReconAfrica in the next 12 months.

Corporate

Due to the ongoing COVID-19 pandemic, Eco continues to keep a strict control over costs throughout the business. This cost drive continues to generate material savings and has ensured that Eco remains well capitalised with a strong balance sheet.

Gil Holzman, President and Chief Executive Officer of Eco Atlantic, commented:

"The Company remains well placed to capitalise on its strategic acreage in both Guyana and Namibia; both prolific hydrocarbon provinces. With no debt and strong cash reserves, Eco remains fully funded for its further near-term drilling plans in Guyana and continues to evaluate additional value enhancing opportunities.

"In Guyana, arguably one the most attractive exploration and production regions in the world in the past five years, we are excited to recommence drilling activity in due course and we are aiming to define targets through reprocessing and we hope to have target selection in the next six months allowing us to begin drilling preparation in the second half of 2021.

"In Namibia, we have seen a ramp up in activity by other operators towards their respective drilling programmes and we expect any success here to considerably benefit Eco. Namibia continues to become ever more attractive to the major players in the industry, and we look forward to an exciting year of activity in 2021 in country and for Eco.

"Eco's resilient business model, along with its strong management, shareholders, and assets in prolific E&P hotpots, means the Company is well positioned to deliver value for shareholders going forward. We very much look forward to keeping the market up to speed on developments for the remainder of 2020 and into the New Year."

The Company's unaudited financial results for three and six months ended 30 September 2020, together with Management's Discussion and Analysis for the three months and six months to 30 September 2020, are available to download on the Company's website at www.ecooilandgas.com and on Sedar at www.sedar.com.

The following are the Company's Balance Sheet, Income Statements, Cash Flow Statement and selected notes from the annual Financial Statements. All amounts are in US Dollars, unless otherwise stated.

Balance Sheet

 
September 30,
 
 
March 31,
 
 
April 1,
 

 
2020
 
 
2020
 
 
2019
 

Assets

 
Unaudited
 
 
Audited
 
 
Audited
 

Current assets

Cash and cash equivalents

 
 
17,192,996
 
 
 
18,667,016
 
 
 
18,750,453
 

Short-term investments

 
 
52,760
 
 
 
52,737
 
 
 
56,098
 

Government receivable

 
 
18,741
 
 
 
19,276
 
 
 
24,821
 

Amounts owing by licence partners, net

 
 
21,809
 
 
 
45,596
 
 
 
–
 

Accounts receivable and prepaid expenses

 
 
135,254
 
 
 
46,262
 
 
 
60,678
 

 
 
17,421,560
 
 
 
18,830,887
 
 
 
18,892,050
 

Petroleum and natural gas licences

 
 
1,117,171
 
 
 
1,117,171
 
 
 
1,117,171
 

Total Assets

 
 
18,538,731
 
 
 
19,948,058
 
 
 
20,009,221
 

Liabilities

Current liabilities

Accounts payable and accrued liabilities

 
 
131,192
 
 
 
350,242
 
 
 
317,548
 

Advances from and amounts owing to licence partners, net

 
 
339,469
 
 
 
–
 
 
 
845,524
 

Total Liabilities

 
 
470,661
 
 
 
350,242
 
 
 
1,163,072
 

Equity

Share capital

 
 
59,099,725
 
 
 
59,099,725
 
 
 
37,509,183
 

Restricted Share Units reserve

 
 
267,669
 
 
 
267,669
 
 
 
83,597
 

Warrants

 
 
53,026
 
 
 
53,026
 
 
 
39,570
 

Stock options

 
 
2,597,644
 
 
 
2,542,824
 
 
 
2,387,837
 

Foreign currency translation reserve

 
 
(1,205,801)
 
 
 
(1,117,859
)
 
 
–
 

Accumulated deficit

 
 
(42,744,193)
 
 
 
(41,247,569
)
 
 
(21,174,038
)

Total Equity

 
 
18,068,070
 
 
 
19,597,816
 
 
 
18,846,149
 

Total Liabilities and Equity

 
 
18,538,731
 
 
 
19,948,058
 
 
 
20,009,221
 

Income Statement

 
Three months ended
 
 
Six months ended
 

 
September 30,
 
 
September 30,
 
 
 
 

 
2020
 
 
2019
 
 
2020
 
 
2019
 

 
Unaudited
 
 
Unaudited
 

Revenue

Interest income

 
 
7,247
 
 
 
101,799
 
 
 
35,656
 
 
 
228,884
 

 
 
7,247
 
 
 
101,799
 
 
 
35,656
 
 
 
228,884
 

Operating expenses:

Compensation costs

 
 
141,322
 
 
 
259,487
 
 
 
313,626
 
 
 
420,527
 

Professional fees

 
 
87,799
 
 
 
219,355
 
 
 
120,414
 
 
 
236,119
 

Operating costs

 
 
330,738
 
 
 
5,189,188
 
 
 
850,415
 
 
 
11,368,546
 

General and administrative costs

 
 
142,267
 
 
 
358,545
 
 
 
229,270
 
 
 
752,831
 

Share-based compensation

 
 
42,177
 
 
 
5,611,560
 
 
 
54,820
 
 
 
5,619,111
 

Foreign exchange gain

 
 
(45,298)
 
 
 
220,535
 
 
 
(36,265)
 
 
 
181,965
 

Total expenses

 
 
699,005
 
 
 
11,858,671
 
 
 
1,532,280
 
 
 
18,579,099
 

Net loss and comprehensive loss

 
 
(691,758)
 
 
 
(11,756,872
)
 
 
(1,496,624)
 
 
 
(18,350,215
)

Basic and diluted net loss per share attributable to equity holders of the parent

 
 
(0.00)
 
 
 
(0.06
)
 
 
(0.01)
 
 
 
(0.10
)

Weighted average number of ordinary shares used in computing basic and diluted net loss per share

 
 
184,697,723
 
 
 
182,038,204
 
 
 
184,697,723
 
 
 
181,112,949
 

Cash Flow Statement

 
Six months ended
 

 
September 30,
 

 
2020
 
 
2019
 

 
Unaudited
 

Cash flow from operating activities

Net loss from operations

 
 
(1,496,624)
 
 
 
(18,350,215
)

Items not affecting cash:

Share-based compensation

 
 
54,820
 
 
 
5,619,111
 

Warrants issued for services

 
 
 
 
 
 
–
 

Changes in non???cash working capital:

Government receivable

 
 
535
 
 
 
(7,154
)

Accounts payable and accrued liabilities

 
 
(219,050)
 
 
 
(207,303
)

Accounts receivable and prepaid expenses

 
 
(88,992)
 
 
 
23,014
 

Advance from and amounts owing to licence partners

 
 
339,469
 
 
 
903,619
 

 
 
(1,409,842)
 
 
 
(12,018,929
)

Cash flow from financing activities

Net proceeds from Private Placement

 
 
–
 
 
 
15,935,765
 

Proceeds from the exercise of stock options

 
 
–
 
 
 
53,971
 

Proceeds from the exercise of warrants

 
 
–
 
 
 
120,612
 

 
 
–
 
 
 
16,110,348
 

Increase (decrease) in cash and cash equivalents

 
 
(1,409,842)
 
 
 
4,091,419
 

Foreign exchange differences

 
 
(64,178)
 
 
 
305,733
 

Cash and cash equivalents, beginning of period

 
 
18,667,016
 
 
 
18,750,453
 

Cash and cash equivalents, end of period

 
 
17,192,996
 
 
 
23,147,605
 

Notes to the Financial Statements

Basis of Preparation

The condensed consolidated interim financial statements of the Company have been prepared on a historical cost basis with the exception of certain financial instruments that are measured at fair value. Historical cost is generally based on the fair value of the consideration given in exchange for assets.

Summary of Significant Accounting Policies

Critical accounting estimates

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively from the period in which the estimates are revised. The following are the key estimate and assumption uncertainties considered by management.

Change in functional currency assessment

The functional currency of the Company and its subsidiaries represent the currency of the primary economic environment in which each entity operates. Through to March 31, 2020, all entities were considered to have a functional currency of Canadian Dollars. On March 31, 2020, the Company determined the United States Dollar ("USD") to be the functional currency for Eco Guyana based on the increased expenditures incurred in USD which is expected to continue in the foreseeable future. On April 1, 2020, the Company determined the USD to be the functional currency for Eco (Atlantic) Oil and Gas Ltd, based on the increase in USD denominated spending as of April 1, 2020. On April 1, 2020, the Company also determined the USD to be the functional currency of Eco Guyana Oil & Gas (Barbados) Ltd, since this entity is 100% owned by Eco Atlantic, and is the 100% owner of Eco Guyana, both of which have functional currencies denominated in USD. The change in estimate has been applied on a prospective basis effective April 1, 2020.

Effective April 1, 2020, the Company also changed its presentation currency from Canadian Dollars to USD. The change in presentation currency is to better reflect the Company's business activities and to improve investors' ability to compare the Company's results to its peers. This change has been applied retroactively as if the Company's new presentation currency has always been the Company's presentation currency.

**ENDS**

For more information, please visit www.ecooilandgas.com or contact the following:

Eco Atlantic Oil and Gas

c/o Celicourt +44 (0) 20 8434 2754

Gil Holzman, CEO

Colin Kinley, COO

Alice Carroll, Head of Marketing and IR

+44(0)781 729 5070 | +1 (416) 318 8272

Strand Hanson Limited (Financial & Nominated Adviser)

+44 (0) 20 7409 3494

James Harris

James Bellman

Berenberg (Broker)

+44 (0) 20 3207 7800

Matthew Armitt

Detlir Elezi

Celicourt (PR)

+44 (0) 20 8434 2754

Mark Antelme

Jimmy Lea

Hannam & Partners (Research Advisor)

Neil Passmore

+44 (0) 20 7905 8500

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

Notes to editors:

About Eco Atlantic:

Eco Atlantic is a TSX-V and AIM quoted Oil & Gas exploration and production Company with interests in Guyana and Namibia, where significant oil discoveries have been made.

The Group aims to deliver material value for its stakeholders through oil exploration, appraisal and development activities in stable emerging markets, in partnership with major oil companies, including Tullow, Total and Azinam.

In Guyana, Eco Guyana holds a 15% Working Interest alongside Total (25%) and Operator Tullow Oil (60%) in the 1,800 km2 Orinduik Block in the shallow water of the prospective Suriname-Guyana basin. The Orinduik Block is adjacent and updip to ExxonMobil Operated Stabroek Block, on which eighteen discoveries have been announced and over 9 Billion BOE of oil equivalent recoverable resources are estimated. First oil production commenced in December 2019 from the deep-water Liza Field, less than three years from FID.

Jethro-1 was the first major oil discovery on Orinduik Block. The Jethro-1 encountered 180.5 feet (55 meters) of net high-quality oil pay in excellent Lower Tertiary sandstone reservoirs which further proves recoverable oil resources. Joe-1 is the second discovery on the Orinduik Block and comprises high quality oil-bearing sandstone reservoir with a high porosity of Upper Tertiary age. The Joe-1 well encountered 52 feet (16 meters) of continuous thick sandstone which further proves the presence of recoverable oil resources.

In Namibia, the Company holds interests in four offshore petroleum licences totalling approximately 25,000km2 with over 2.3bboe of prospective P50 resources in the Walvis Basin. These four licences, Cooper, Guy, Sharon and Tamar are being developed alongside partners Azinam and NAMCOR. Eco has been granted a drilling permit on its Cooper Block (Operator).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Eco (Atlantic) Oil and Gas Ltd.

ReleaseID: 618174

VANCOUVER, BC / ACCESSWIRE / November 24, 2020 / Grande West Transportation Group Inc. (TSX.V:BUS) (OTCQX:GWTNF) (FRA:6LG) – November 24, 2020: ("Grande West" or the "Company"), a Canadian manufacturer of mid-sized multi-purpose transit vehicles for sale in Canada and the United States, is pleased to announce the Vicinity LightningTM Electric Vehicle ("EV") specifications and is now for sale in Canada and the United States.

The Vicinity LightningTM EV, the first electric bus for Grande West, is the newest model in the Grande West portfolio and is officially being introduced to the world (See product presentation here https://vicinitybus.com/models/vicinity-lightning-ev/). The premiere of the vehicle is a landmark for Grande West and for the industry in the transitioning towards zero-emission transport. The Vicinity LightningTM will be an environmentally friendly alternative for diesel vehicles currently used in this segment.

The Vicinity LightningTM was designed from the ground up to be a cost effective, user friendly vehicle. The design will allow it to fit into any standard transit garage with no major infrastructural electrical upgrades. Grande West has partnered with world class industry leaders to engineer this highly advanced vehicle. Time and forethought were given to the design and engineering process with the customer in mind and the result is the industry-changing Vicinity LightningTM bus. The Company's sales team has started the process of introducing the product to prospective clients in the United States and Canada.

We are pleased to invite interested listeners to the presentation to be given by our Chief Operating Officer, Jonathan Leskewich. Following our financial and corporate update on the conference call today, a question and answer period will include the Vicinity LightningTM.

The conference call begins today at 11:00 AM EST. The call-in number is (877) 407-0782 or (201) 689-8567 (international), the webcast can be accessed at https://www.webcaster4.com/Webcast/Page/2233/38806 . A replay of the call will be available for 30 days at the webcast link or by calling (877) 481-4010 and entering PIN# 38806.

About Grande West Transportation Group

Grande West Transportation is a Canadian company that designs and engineers mid-size multi-purpose transit vehicles for public and commercial enterprises. Grande West utilizes world-class manufacturing partners to produce the Purpose-Built Vicinity heavy-duty bus available in clean diesel, gas, and CNG drive systems. The Vicinity LT EV with an electric propulsion drive system is available for 2021 deliveries.

The Company has been successful in supplying Canadian municipal transportation agencies and private operators with new buses. Grande West is compliant to Buy America certification, and with a strong distribution chain in the U.S., is actively pursuing opportunities in public and private transit fleet operations that would benefit from Grande West's vehicles.
www.grandewest.com

For investor relations, please contact:

Paradox Public Relations Inc.
Karl Mansour
Managing Director
Ph: (514) 341-0408 or 1-866-460-0408
IR@grandewest.com

Company contact:

Grande West Transportation
John LaGourgue
VP Corporate Development
Ph: 604-288-8043
IR@grandewest.com

Neither the TSX-V nor its Regulation Service Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein, including without limitation, statements regarding the use of proceeds from the Private Placement, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects," "anticipates," "believes," "intends," "estimates," "potential," "possible," and similar expressions, or statements that events, conditions, or results "will," "may," "could," or "should" occur or be achieved. Forward-looking statements involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.

Important factors that could cause actual results to differ materially from Grande West's expectations include uncertainties relating to the receipt of final approval from the TSX-V; and other risk and uncertainties disclosed in Grande West's reports and documents filed with applicable securities regulatory authorities from time to time. Grande West's forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made. Grande West assumes no obligation to update the forward-looking statements or beliefs, opinions, projections, or other factors, should they change, except as required by law.

SOURCE: Grande West Transportation Group Inc.

ReleaseID: 618069